PPHM - I love dog fights - currently - .70 - - - -OT
"""""It discovered the discrepancies while preparing for a meeting with regulators. Peregrine said the source appears to be tied to an independent, third party it did not name that was contracted to code and distribute the product.
The company also said the issue won't have an impact on other on-going bavituximab studies.
Peregrine also is studying bavituximab as a primary treatment for lung cancer. It is conducting clinical trials of the drug as a treatment for cancers of the pancreas, liver, prostate, breast, and for the viral infection for hepatitis C.
"Today's news comes as a shock and we believe represents a major blow to confidence in the bavituximab program until the discrepancies can hopefully be worked out," the analyst wrote.
Pantginis also noted that there is no indication about the extent of the issue and whether it ultimately affects the drug's survival benefit.
On Friday, shares of Peregrine peaked at $5.50, their highest price since May 2009. The stock traded as low as 39 cents in April."""""
Notice the stock has had a pause at the .70 level, hitting a resistance level form a hard drop on March 5th. The stock continued a decline back in March from that .70 level but PPHM has held .70 - .74 since last Wed. Watch for any uptick. Also, any clarification form management regarding the flawed 3rd party design results - could put instant gratification back in the pps quickly. Even if the data is still flawed and yet they outline the ENTIRE flaw to the 3rd party - could be enough to rejuvenate trust in the mngmt - and the pps. WATCH IT!